¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
5/7 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2022-05-04
Á¶È¸¼ö
149


¾È³çÇϼ¼¿ä ³ª·¡ÀÔ´Ï´Ù.

À̹øÁÖ Á¦°¡ ¹ßÇ¥ÇÏ°Ô µÉ ³í¹®Àº ¿ÃÇØ Cell reports¿¡ °ÔÀçµÈ "Interferon-g promotes monocyte-mediated lung injury during influenza infection"À̶ó´Â Á¦¸ñÀÇ ³í¹®À¸·Î, ÃÖ±Ùµé¾î influenza A virus (IAV) °¨¿°»óȲ¿¡¼­ IFN-gÀÇ pathogenicÇÑ functionÀÌ ¹àÇôÁö°í ÀÖ´Â °¡¿îµ¥, À̸¦ ¸Å°³ÇÏ´Â ¼¼Æ÷°¡ CCR2+ monocyte¿Í monocyte-derived DC¶ó´Â »ç½ÇÀ» ¹àÈù ³í¹®À¸·Î, ÀÌ ¼¼Æ÷¸¦ ¸Å°³·Î lung barrier integrity°¡ ¹«³ÊÁ® 2Â÷ ¹ÚÅ׸®¾Æ °¨¿°»óȲ¿¡µµ Ãë¾àÇØ Áú ¼ö ÀÖÀ½À» ¸»ÇÏ°í ÀÖ½À´Ï´Ù.

±âÁ¸¿¡ ¾Ë°íÀÖ´ø IFN-gÀÇ ¿ªÇÒ°ú ´Ù¼Ò »óÃæµÇ´Â ºÎºÐÀÌ ÀÖÁö¸¸, monocyte¿Í epithelial cellÀÇ interactionÀ» ´Ù·ç¾ú´Ù´Â Á¡°ú À̸¦ secondary infection±îÁö ¿¬°á½ÃÄÑ Ç®¾î³½ ³»¿ëÀÌ Èï¹Ì·Î¿ö ¼Ò°³½ÃÄѵ帮°íÀÚ ¼±Á¤ÇÏ°Ô µÇ¾ú½À´Ï´Ù.

Àß ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.

¸µÅ©: https://www.sciencedirect.com/science/article/pii/S2211124722001838?via%3Dihub
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
5/7 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¿µÁø ÀÔ´Ï´Ù. Á¦°¡ À̹øÁÖ Åä¿äÀÏ¿¡ ¹ßÇ¥ ÇÒ ³í¹®Àº ÀÛ³âJournal of Allergy and Clinical Immunology (JACI)¿¡ ÃâÆÇµÈ "Cannabinoid receptor 2 engagement promotesgroup 2 innate lymphoid cell expansion andenhances airway hyperreactivity" ÀÔ´Ï´Ù. ÇØ´ç ³í¹®¿¡¼­´Â l..
ÀÌÀü±Û
4/30 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. À̹øÁÖ¿¡ Á¦°¡ ÁغñÇÑ ³í¹®ÀÇ Á¦¸ñÀº "Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity" ÀÌ¸ç ¿ÃÇØ 2¿ù¿¡ Immunity¿¡ ÃâÆÇµÈ ³í¹®ÀÔ´Ï´Ù. cDC1°ú cDC2ÀÇ ¿ªÇÒÀº ÃÖ±Ù ¸¹..